In the trial, the improvement in FEV1, the primary endpoint, was prominent in the 200ug (p=0.019) and 400ug (p=0.001) BID dose groups. However, for the expected therapeutic dose,
Degarelix is a gonadtrophin-releasing hormone (GnRH) blocker with a subcutaneously injectable formulation. In January 2006, Astellas and Ferring International Center entered into a license agreement that gives Astellas
In its CRL, the FDA has informed Vivus that the NDA for Qnexa cannot be approved in its present form. The CRL included the following areas: clinical, labeling,
Following the establishment of the Hangzhou Sanofi Minsheng Consumer Healthcare joint venture, the acquisition of BMP Sunstone will make sanofi-aventis a consumer healthcare company in China, with a
Bristol-Myers Squibb and Otsuka Pharmaceutical are collaborative partners in the commercialisation of Sprycel in the US, Japan and major European countries. Sprycel was discovered and developed by Bristol-Myers
Humira, a fully human anti-TNF monoclonal antibody that exerts its effects by neutralising TNF, is a cytokine that plays a central role in inflammatory responses. Humira is already
The Multi-Source Injectables business comprises a portfolio of 41 products in over 150 dosage strengths and forms across 23 therapeutic areas. The business’ product portfolio also includes several
Lubrizol has posted a net income of $211.8m for the third quarter 2010, or $3.08 per diluted share, compared to $170.5m, or $2.46 per diluted share, for the
North American-based SOHM is a generic pharmaceutical manufacturer that produces and markets generic drugs, covering all major treatment categories. SOHM Corporate Strategy vice president Shailesh Shah said that
Bemis has posted a net income of $61.42m for the third quarter 2010, or $0.56 per diluted share, compared to $35.84m, or $0.33 per diluted share, for the
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.